Try our mobile app

Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12

Published: 2021-12-03 19:51:00 ET
<<<  go to LLY company page

Expanded EUA includes both treatment of patients with COVID-19 and post-exposure prophylaxis (PEP) in high-risk pediatric and infant patients

INDIANAPOLIS, Dec. 3, 2021 /PRNewswire/ -- The U.S.Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab administered together to include certain high-risk pediatric patients from birth to